WMA
BBIO icon

Wealth Management Associates’s BridgeBio Pharma BBIO Stock Holding History

Wealth Management Associates’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$801K Buy
10,754
+1,719
+19% +$120K 0.22% 80
2026
Q1 		$671K Buy
9,035
+135
+2% +$9.79K 0.23% 86
2025
Q4 		$681K Hold
8,900
– – 0.24% 79
2025
Q3 		$462K Buy
8,900
+400
+5% +$19.5K 0.16% 114
2025
Q2 		$367K Sell
8,500
-480
-5% -$17.5K 0.14% 136
2025
Q1 		$310K Buy
8,980
+1,435
+19% +$48.4K 0.13% 153
2024
Q4 		$207K Sell
7,545
-2,135
-22% -$55.2K 0.09% 195
2024
Q3 		$246K Sell
9,680
-1,700
-15% -$44.6K 0.11% 177
2024
Q2 		$288K Hold
11,380
– – 0.14% 148
2024
Q1 		$288K Buy
+11,380
New +$387K 0.14% 148

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Wealth Management Associates's BBIO Position: Q2 2026 in Review

Wealth Management Associates increased its BridgeBio Pharma (BBIO) stake by 19% in Q2 2026, buying an estimated $120K and bringing the position to 10,754 shares worth $801K. The position accounts for 0.22% of the portfolio, ranked #80.

Wealth Management Associates first reported a position in BBIO in Q1 2024 and has held it in 10 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Wealth Management Associates held 10,754 shares of BridgeBio Pharma worth $801K as of Q2 2026.
  • Wealth Management Associates bought 1,719 BridgeBio Pharma shares in Q2 2026, an estimated $120K.
  • BridgeBio Pharma made up 0.22% of Wealth Management Associates's portfolio in Q2 2026, its #80 holding.
  • Wealth Management Associates first reported a position in BridgeBio Pharma in Q1 2024 and has held it in 10 quarters since.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Wealth Management Associates's 13F filing for Q2 2026, filed 21 Jul 2026.